Conformis and SITES Medical entered into a non-exclusive development and supply agreement. The companies will incorporate SITES Medical’s proprietary OsteoSync Ti Technology into future Conformis’ cementless total knee replacement.s
OsteoSync™ Ti is a highly porous titanium bone ingrowth material. Its high friction coefficient promotes high initial implant stability and its open pore geometry, combined with micro and nano-texturing, facilitates superior bone ingrowth. OsteoSync Ti has been used in over 50,000 procedures since 2014.
"We are pleased to have entered into this agreement and are looking forward to working with SITES Medical to apply their technology to our future cementless total knee offering," said John Slamin, Senior Vice President, Product Development, of Conformis.
“We are excited to be partnering with Conformis, a company that has brought a high degree of innovation to the joint replacement field,” said Greg Stalcup, President/CEO of SITES Medical. “We look forward to working with the Conformis team to combine our respective technologies to deliver new generations of high performance, cost effective, and OR-efficient products to the market.”